Published in Gene Therapy Weekly, April 27th, 2006
"Intravitreal administration of specific ODNs effectively downregulates gene expression in the retina but does not modulate it exclusively in RGCs. Expression of kynurenine aminotransferase II (KAT II) in RGCs has been well described in the literature," wrote S. Thaler and colleagues, University of Tubingen. "We describe a new method for downregulating cellular KAT II expression via transfection of RGC by retrograde transfer of ODN."
The authors explained,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-04-27)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.